Larisa Geskin, MD of Columbia University Medical Center, New York, NY gives an overview of her talk on chemotherapy for melanoma, squamous cell carcinoma and cutaneous T-cell lymphoma (CTCL) at the 2016 World Congress on Cancers of the Skin (WCCS) and the Congress of the European Association of Dermato-Oncology (EADO) in Vienna, Austria. Dr Geskin explains that chemotherapy may play little role in the management of these diseases, particularly in the case of cutaneous T-cell lymphoma. The multi-agent chemotherapy may only play role in the palliative setting, which is related to the fact that CTCL is a chronic and incurable disease. Therefore, using a potent immunotherapy approach than using toxic chemotherapy. For a subset of patients, mostly end stage patients who do not have other options or patients who are in severe pain, multi-agent chemotherapy can be used.
The role of chemotherapy in cutaneous T-cell lymphoma
